DERM - Dermira, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.72
-0.23 (-2.31%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.95
Open9.79
Bid0.00 x 3100
Ask0.00 x 800
Day's Range9.54 - 9.96
52 Week Range6.00 - 15.48
Volume688,289
Avg. Volume2,184,596
Market Cap521.65M
Beta (3Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-5.35
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.88
Trade prices are not sourced from all markets
  • Dermira (DERM) Q1 2019 Earnings Call Transcript
    Motley Fool15 days ago

    Dermira (DERM) Q1 2019 Earnings Call Transcript

    DERM earnings call for the period ending March 31, 2019.

  • Did You Manage To Avoid Dermira's (NASDAQ:DERM) Painful 63% Share Price Drop?
    Simply Wall St.16 days ago

    Did You Manage To Avoid Dermira's (NASDAQ:DERM) Painful 63% Share Price Drop?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is doubtless a positive to see that the Dermira, Inc. (NASDAQ:DERM) share price has gained some...

  • Thomson Reuters StreetEvents16 days ago

    Edited Transcript of DERM earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Dermira Inc Earnings Call

  • Dermira (DERM) Reports Q1 Loss, Lags Revenue Estimates
    Zacks16 days ago

    Dermira (DERM) Reports Q1 Loss, Lags Revenue Estimates

    Dermira (DERM) delivered earnings and revenue surprises of -13.74% and -6.77%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press16 days ago

    Dermira: 1Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of $1.49 per share. The skin condition drug developer posted revenue of $2.5 million in the period, falling short of Street forecasts. Three ...

  • Business Wire16 days ago

    Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update

    Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update

  • Markit17 days ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Dermira Inc NASDAQ/NGS:DERMView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding DERM are favorable, with net inflows of $898 million. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire23 days ago

    Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report financial results for the quarter ended March 31, 2019 and provide an operational update after market close on Tuesday, May 7, 2019. Dermira also has early-stage research and development programs in other areas of dermatology.

  • Dermira (DERM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks29 days ago

    Dermira (DERM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Dermira (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zackslast month

    NASDAQ Back Above 8,000

    NASDAQ Back Above 8,000

  • Here's Why Dermira Shot Up 62% in March
    Motley Foollast month

    Here's Why Dermira Shot Up 62% in March

    Results from a mid-stage study with a potential new eczema drug gave investors a reason to cheer.

  • Business Wire2 months ago

    Dermira to Present at the 18th Annual Needham Healthcare Conference

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a fireside chat at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 12:50 p.m. ET. Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.

  • Does The Dermira, Inc. (NASDAQ:DERM) Share Price Fall With The Market?
    Simply Wall St.2 months ago

    Does The Dermira, Inc. (NASDAQ:DERM) Share Price Fall With The Market?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you're interested in Dermira, Inc. (NASDAQ:DERM), then you might want to consider its beta (a measure of share price volat...

  • GlobeNewswire2 months ago

    Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced the launch of “Life Unfolds,” a new direct-to-consumer creative campaign designed to generate awareness of QBREXZA™ (glycopyrronium) cloth as a potential treatment option for people living with primary axillary hyperhidrosis, commonly known as excessive underarm sweating. QBREXZA, the first and only, once-daily, topical prescription anticholinergic, is approved by the U.S. Food and Drug Administration (FDA) to treat adult and pediatric patients 9 years of age and older living with this chronic, medical skin condition.

  • GlobeNewswire2 months ago

    Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    MENLO PARK, Calif., March 22, 2019 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • Dermira (DERM) Catches Eye: Stock Jumps 12%
    Zacks2 months ago

    Dermira (DERM) Catches Eye: Stock Jumps 12%

    Dermira (DERM) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

  • GlobeNewswire2 months ago

    Dermira Prices $130.0 Million Public Offering of Common Stock

    MENLO PARK, Calif., March 19, 2019 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • Why Dermira Stock Jumped Again Today
    Motley Fool2 months ago

    Why Dermira Stock Jumped Again Today

    An analyst's upgrade provides another boost to the high-flying biotech stock.

  • Company News For Mar 19, 2019
    Zacks2 months ago

    Company News For Mar 19, 2019

    Companies in the news are: OSTK, FIS, WP, EW and DERM

  • Can Dermira Stock Keep Soaring?
    Motley Fool2 months ago

    Can Dermira Stock Keep Soaring?

    The skincare specialist's experimental eczema treatment hit the mark in mid-stage testing, but what about the road ahead?

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of DERM earnings conference call or presentation 26-Feb-19 9:30pm GMT

    Q4 2018 Dermira Inc Earnings Call

  • GlobeNewswire2 months ago

    Dermira Announces Proposed Public Offering of Common Stock

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it intends to offer $110.0 million of its common stock in an underwritten public offering. Dermira also expects to grant to the underwriters a 30-day option to purchase up to an additional $16.5 million of its common stock in the offering. All of the shares will be offered and sold by Dermira. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Citigroup, Cowen, Cantor Fitzgerald & Co. and Guggenheim Securities are acting as book-runners for the offering.

  • Why Dermira Stock Is Soaring More than 80% Today
    Market Realist2 months ago

    Why Dermira Stock Is Soaring More than 80% Today

    Why Dermira Stock Is Soaring More than 80% TodayShare price movements Today, Dermira (DERM) is trading close to $12.85, ~87.87% higher than its previous closing price, with a market capitalization of $292.48 million. The company is trading 114.19%